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MaOBJECTIVES We report our 8-year experience in transcatheter aortic and mitral valve-in-valve (VinV) implantation.
BACKGROUND Feasibility and good early outcomes associated with transcatheter aortic and mitral VinV implantation
into failed surgical bioprostheses have been conﬁrmed, but the mid-term and long-term outcomes of transcatheter aortic
and mitral VinV is unknown.
METHODS A total of 73 patients with aortic (n ¼ 42) and mitral (n ¼ 31) bioprosthetic valve dysfunction underwent
transcatheter VinV implantation between April 2007 and December 2013. Edwards balloon-expandable transcatheter
valves (Edwards Lifesciences Inc., Irvine, California)were used.Median follow-upwas 2.52 yearswith amaximumof8 years.
RESULTS Seventy-two patients (mean age 79.7  9.4 years, 32 women) underwent successful VinV implantation
(success rate 98.6%). At 30 days, all-cause mortality was 1.4%, disabling stroke 1.4%, life-threatening bleeding 4.1%,
acute kidney injury requiring hemodialysis 2.7%, and coronary artery obstruction requiring intervention 1.4%. No patient
had greater than mild paravalvular leak. Estimated survival rates were 88.9%, 79.5%, 69.8%, 61.9%, and 40.5% at 1, 2,
3, 4, and 5 years, respectively. The small surgical valve size (19 and 21 mm) was an independent risk factor for reduced
survival in aortic VinV patients. At 2-year follow-up, 82.8% of aortic and 100% of mitral VinV patients were in New York
Heart Association functional class I or II.
CONCLUSIONS Transcatheter VinV for failed surgical bioprostheses can be performed safely with a high success rate
and minimal early mortality and morbidity. Transcatheter VinV provides encouraging mid-term clinical outcomes in this
high-risk elderly cohort of patients. Transcatheter VinV is an acceptable alternative therapy for failed aortic or mitral
bioprostheses in selected high-risk patients. (J Am Coll Cardiol Intv 2015;8:1735–44) © 2015 by the American College of
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ABBR EV I A T I ON S
AND ACRONYMS
AVR = aortic valve
replacement
LVEF = left ventricular ejection
fraction
MVR = mitral valve
replacement
NYHA = New York Heart
Association
TAVI = transcatheter aortic
valve implantation
VinV = valve-in-valve
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1736patients are often declined, or not referred,
for redo aortic valve replacement (AVR) or
mitral valve replacement (MVR).
The feasibility and good early outcomes of
transcatheter aortic and mitral valve-in-valve
(VinV) implantation into failed surgical bio-
prostheses have been demonstrated (3–12). A
lesser invasive approach for failed surgical
bioprostheses is desirable for this ever-
expanding high-risk elderly population.SEE PAGE 1745We report our 8-year experience in trans-
catheter aortic and mitral VinV implantation in 73
consecutive patients with surgical biological valve
dysfunction.
METHODS
PATIENT SELECTION. From April 2007 to December
2013, 73 consecutive patients with symptomatic se-
vere aortic (n ¼ 42) and mitral (n ¼ 31) bioprosthetic
valve dysfunction underwent transcatheter aortic
and mitral VinV implantation, respectively, at a single
center (St. Paul’s Hospital, Vancouver, British Col-
umbia, Canada). All patients had previous AVR or
MVR with bioprostheses and were reviewed at our
multidisciplinary transcatheter valve rounds. The
indications for reoperative AVR or MVR generally
followed the American College of Cardiology/Amer-
ican Heart Association guidelines for valve surgery
(13). Patients who were deemed to be too high risk for
conventional redo valve replacement by cardiac sur-
geons were considered as potential candidates for
transcatheter VinV implantation. Written and in-
formed consents were obtained. Echocardiography
and clinical follow-up was performed pre- and post-
operatively.
VinV IMPLANTATION. Balloon-expandable trans-
catheter valves (Edwards Lifesciences, Inc., Irvine,
California) were used in all cases. Various generations
of valves and delivery systems were used from April
2007 to December 2013. The ﬁrst-in-human aortic and
mitral VinV implantations were performed by the
implantation of 23- and 26-mm Cribier-Edwards
equine valves, respectively, using a transapical ap-
proach (4,14). In all subsequent cases, bovine
Edwards SAPIEN and SAPIEN XT valves were
implanted through either a transfemoral or trans-
apical approach. Transapical access was the only
approach that was used for mitral VinV implantation.
All operations were performed in our hybrid oper-
ating room equipped with standby cardiopulmonarybypass support. The techniques of transcatheter
aortic and mitral VinV implantation were described
previously (4,14,15). Balloon valvuloplasty of the
bioprosthesis was utilized in our initial experience,
but was subsequently not utilized during transapical
VinV implantation. During transfemoral aortic VinV
implantation, balloon valvuloplasty was used in some
cases with critical bioprosthetic stenosis. Selection of
an appropriately sized SAPIEN or SAPIEN XT valve
depended on the internal diameter of the pre-existing
surgical bioprosthesis as reported by the manufac-
turer. Fluoroscopic and/or transesophageal echo-
cardiography imaging were sufﬁcient for valve
positioning. Intraoperative conventional aortography
was not performed during transapical VinV implan-
tation, but occasionally performed prior to trans-
femoral aortic VinV implantation and/or following
aortic VinV implantation to assess coronary ostia.
Contrast was not utilized during mitral VinV pro-
cedures. Optimal positioning of the transcatheter
valve was achieved with rapid ventricular pacing
immediately prior to valve deployment. Post-
operatively, patients were instructed to take aspirin
indeﬁnitely and clopidogrel for at least 3 months.
Warfarin and aspirin were used for mitral VinV im-
plantation or if other indications were present, such
as atrial ﬁbrillation.
FOLLOW-UP AND DATA COLLECTION. All patients
were followed-up by transcatheter valve therapy
team staff or clinical fellows. Follow-up included
telephone interviews and ofﬁce visits. Data were
prospectively collected and entered into our trans-
catheter aortic valve implantation (TAVI) database.
The median follow-up period was 2.52 years, with
longest follow-up of 8 years. Procedural success and
complications were reported according to Valve Aca-
demic Research Consortium-2 deﬁnitions (16).
STATISTICAL ANALYSIS. Continuous variables were
summarized using mean  SD or median with inter-
quartile range (IQR) and compared between aortic
surgical valve sizes (#21, 23, or >23 mm) or surgical
types (aortic valve vs. mitral valve) with the use of the
Student t test or Wilcoxon rank sum test. Categorical
variables were summarized using frequencies and
percentages and compared between surgical valve
sizes or surgical types with the use of the Fisher exact
test or chi-square test. The Kaplan-Meier method was
used to obtain the survival curves on the basis of
time-to-event data. Cox proportional hazards regres-
sion analyses were conducted to evaluate risk factors
inﬂuencing mid-term survival rates. The proportional
hazards assumption of the Cox regressions was
satisﬁed for the models. Follow-up echocardiographic
TABLE 1 Baseline Characteristics
All (n ¼ 73) Aortic (n ¼ 42) Mitral (n ¼ 31)
Age, yrs 79.7  9.4 80.5  9.8 78.7  8.8
Male 41 (56.2) 28 (67.7) 13 (42.0)
Diabetes mellitus 17 (23.3) 10 (23.8) 7 (22.6)
Coronary artery disease 45 (61.6) 29 (69.0) 16 (51.6)
PASP $60 mm Hg 20 (27.4) 7 (16.7) 13 (41.9)
Coronary artery bypass grafting 32 (43.8) 19 (45.2) 13 (41.9)
NYHA functional class III or IV 69 (94.5) 39 (92.9) 30 (96.8)
COPD (moderate þ severe) 11 (15.1) 4 (9.5) 7 (22.6)
Cerebrovascular accident 17 (23.3) 7 (16.7) 10 (32.3)
Surgical valve size <23 mm 8 (11.0) 8 (19.0) 0 (0.0)
Peripheral vascular disease 17 (23.3) 13 (31.0) 4 (12.9)
Left ventricular ejection fraction, % 60 (45, 65) 57.5 (47, 65) 60 (40, 65)
Creatinine 100–149 mmol/l 32 (43.8) 20 (47.6) 12 (38.7)
Creatinine $150 mmol/l 11 (15.1) 9 ( 21.4) 2 (6.5)
STS score, % 9.6 (5.9, 13.4) 9.6 (6.2, 11.4) 9.7 (5, 16.6)
Failed surgical valves
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1737data were evaluated by the paired t test or Wilcoxon
signed rank test, and the longitudinal model with
covariance structure for continuous variables. The
covariance structure, heterogeneous compound
symmetry was chosen for modeling for pulmonary
artery systolic pressure (PASP), and the covariance
structure, autoregressive with heterogeneous vari-
ance was selected for modeling for mean gradient.
Dichotomized New York Heart Association (NYHA)
data obtained at baseline and follow-ups were
compared using McNemar’s test. All tests were
2-sided, and a p value <0.05 was considered statisti-
cally signiﬁcant. All statistical analyses were per-
formed using SAS software version 9.4 (SAS Institute,
Cary, North Carolina) and R software version 3.1.1
(R Foundation for Statistical Computing, Vienna,
Austria).Stenosis 34 (46.6) 22 (52.4) 12 (38.7)
Regurgitation 27 (37.0) 13 (31.0) 14 (54.2)
Mixed 12 (16.4) 7 (16.7) 5 (16.1)
Values are mean  SD, n (%), or median (quartile 1, quartile 3).
COPD¼ chronic obstructive pulmonary disease; NYHA¼ New York Heart Association; PASP ¼ pulmonary artery
systolic pressure; STS ¼ Society of Thoracic Surgeons.RESULTS
PATIENTS. The mean ages were 80.5  9.8 years and
78.7  8.8 years in patients undergoing aortic and
mitral VinV implantation, respectively. Patients un-
dergoing mitral VinV were more likely to be female
relative to those undergoing aortic VinV (58.0%
vs. 32.3%). Surgical bioprosthetic valves included
Carpentier-Edwards porcine and pericardial (Edwards
Lifesciences, Inc., Irvine, California), Mosaic (Med-
tronic, Minneapolis, Minnesota), Mitroﬂow (Sorin
Group, Milan, Italy), Trifecta (St. Jude Medical, Min-
neapolis, Minnesota), and Ionescu-Shiley (Shiley Inc.,
Irvine, California) valves. Surgical aortic and mitral
valves were implanted 13.4  5.5 years and 9.3  3.1
years before the VinV procedure, respectively. Base-
line demographics are listed in Table 1.
The median of the calculated Society of Thoracic
Surgeons risk score was 9.6 (IQR: 6.2 to 11.4) and 9.7
(IQR: 5.0 to 16.6) in patients with aortic and mitral
VinV implantation, respectively. Mechanisms of bio-
prosthetic failure included stenosis, regurgitation,
and mixed stenosis and regurgitation (Table 1). No
patient had signiﬁcant perivalvular bioprosthetic
regurgitation. The manufacturers’ labeled size ranged
from 19 to 29 mm and 25 to 33 mm for aortic and
mitral bioprostheses, respectively.
INTRAOPERATIVE OUTCOMES. The transcatheter
valve was successfully implanted within the failed
surgical valve in 72 of 73 patients (98.6%). Major
intraoperative complications were observed in 3 pa-
tients (4.1%). Embolization of a SAPIEN valve into
the left ventricle occurred in 1 patient due to an
extremely poor implantation angle during a trans-
apical aortic VinV procedure. Emergency conversionto open-heart surgery was required, and the patient
survived. Left main coronary obstruction occurred in
1 patient following implantation of a SAPIEN valve
into a Sorin Mitroﬂow aortic valve. Despite emer-
gency conversion to open-heart AVR, the patient died
the following day (17). A third patient with a failed
mitral bioprosthesis required implantation of a sec-
ond valve because of an initial implant placed distal
(more apical) to the mitral annulus.
EARLY CLINICAL OUTCOMES. Life threatening
bleeding (packed red blood cells $4 U) and major
bleeding (2 to 3 U) occurred in 3 (4.1%) aortic and 6
(8.2%) mitral VinV patients. No patient required
reoperation for bleeding or tamponade. One patient
(1.4%) had an in-hospital disabling stroke following
mitral VinV implantation. Two patients (2.7%) had
stage III acute kidney injury by Valve Academic
Research Consortium-2, requiring temporary renal
replacement therapy. One patient with chronic atrial
ﬁbrillation required a pacemaker following mitral
VinV implantation due to pre-existing sick sinus
syndrome. One patient, who had left main obstruc-
tion and was converted to open-heart surgery, died
on the ﬁrst day following the procedure, resulting in
an overall 30-day mortality of 1.4% (Table 2). The
median of the hospital length of stay was 5 days (IQR:
3 to 7 days).
MID-TERM CLINICAL OUTCOMES. Overall survival in
73 patients who underwent either aortic or mitral
FIGURE 1 Kaplan-Meier Survival Rates Following Transcatheter VinV
(A) All 73 patients, (B) aortic versus mitral patients, (C) patients with di
VinV ¼ valve-in-valve.
TABLE 2 Early and Late Complications
Aortic VinV (n ¼ 42) Mitral VinV (n ¼ 31)
30 Days >30 Days 30 Days >30 Days
Major bleeding (2–3 U PRBC) 0 0 6 0
Life-threatening bleeding ($4 U PRBC) 2 1 1 0
Conversion to open surgery 1 0 0 0
Valve migration 0 0 0 1
ARF requiring hemodialysis 1 0 1 0
Myocardial infarction 0 0 0 0
Major vascular complication 0 0 0 0
Disabling stroke 0 0 1 1
Left main obstruction 1 0 0 0
Endocarditis 0 0 0 0
Valve thrombosis 0 2 0 2
Failed valve (structural) 0 1 0 0
THV-in-THV deployment 0 0 1 0
Permanent PM implantation 0 0 1 0
Values are n.
ARF ¼ acute renal failure; PM ¼ pacemaker; PRBC ¼ packed red blood cells; THV ¼ transcatheter heart valve;
VinV ¼ valve-in-valve.
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1738VinV implantation was 88.9%, 79.5%, 69.8%, 61.9%,
and 40.5% at 1, 2, 3, 4, and 5 years, respectively
(Figure 1A). Peripheral vascular disease and previous
stroke were independent risk factors for reduced mid-
term survival, with hazard ratios of 3.2 and 3.0,
respectively (Table 3). Female patients appeared to
have relatively poor survival (Figure 1D). There was
no signiﬁcant difference in late survival between
patients undergoing aortic and mitral VinV implan-
tation (Figure 1B). The median survival rates were 4.5
and 4.4 years following aortic and mitral VinV im-
plantation, respectively.
Multivariate model showed that the small size
(19 and 21 mm) of failed aortic surgical valves was
an independent risk factor for reduced mid-term
survival, with a hazard ratio of 6.2 in patients with
aortic VinV implantation (Table 4). Poorer estimated
survival was observed in patients who had small
aortic surgical valves (19 and 21 mm) relative to
those with surgical valves of $23 mm (p ¼ 0.046)Implantation
fferent surgical valve sizes, and (D) male versus female patients.
TABLE 3 Factors Inﬂuencing Survival (n ¼ 73)
Univariate Model Multivariate Model
Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Female 2.136 (0.904–5.049) 0.084 2.570 (0.983–6.719) 0.054
PVD 1.466 (0.590–3.644) 0.411 3.153 (1.070–9.288) 0.037
PASP $60 mm Hg 1.880 (0.775–4.556) 0.162 2.941 (0.963–8.982) 0.058
LVEF <50% 1.459 (0.611–3.482) 0.395 2.658 (0.891–7.931) 0.080
COPD (moderate þ severe) 0.645 (0.151–2.763) 0.555
CABG  CAD 1.231 (0.479–3.160) 0.666
Creatinine 100–149 mmol/l 1.116 (0.325–3.835) 0.862
Creatinine $150 mmol/l 1.532 (0.593–3.958) 0.379
DM 1.447 (0.530–3.948) 0.471
CVA 2.001 (0.794–5.046) 0.142 2.956 (1.033–8.461) 0.043
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; CVA ¼
cerebrovascular accident; DM ¼ diabetes mellitus; LVEF ¼ left ventricular ejection fraction; PVD ¼ peripheral
vascular disease; other abbreviations as in Table 1.
TABLE 4 Factors Inﬂuencing the Survival of Aortic VinV Patients (n ¼ 42)
Univariate Model Multivariate Model
Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Female 2.485 (0.614–10.07) 0.202
PVD 2.752 (0.747–10.14) 0.128
PASP $60 mm Hg 2.906 (0.692–12.21) 0.145
LVEF <50% 1.742 (0.489–6.207) 0.392 2.945 (1.472–25.99) 0.049
CABG  CAD 0.784 (0.177–3.475) 0.749
Creatinine 100–149 mmol/l 0.925 (0.127–6.749) 0.938
Creatinine $150 mmol/l 2.126 (0.428–10.57) 0.357
DM 2.601 (0.639–10.59) 0.182 4.779 (0.741–11.71) 0.125
CVA 0.773 (0.995–6.304) 0.810
Surgical valve size <23 mm 3.420 (0.951–12.30) 0.060 6.186 (1.001–22.82) 0.013
Abbreviations as in Tables 1 and 3.
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1739(Figure 1C). There were signiﬁcant smaller aortic valve
area and higher mean transaortic pressure gradient
following aortic VinV implantation in patients with
surgical valve sizes of 19 and 21 mm relative to those
with surgical valve sizes of >23 mm (Table 5). There
was no difference in survival following aortic VinV
implantation between the patients with bioprosthetic
stenosis and those with bioprosthetic regurgitation.
Cumulative valve-related complications were listed
in Table 2. Delayed valve migration occurred in 1 pa-
tient following uneventful mitral VinV implantation
with a 26-mm SAPIEN prosthesis into a failed 27-mm
Edwards Perimount pericardial valve (Edwards Life-
sciences, Inc.). In this patient, acute heart failure
2 months after the procedure resulted from atrial
migration of the SAPIEN valve and severe peri-
paravalvular regurgitation. A second transapical
mitral VinV implantation with a 29-mm SAPIEN valve
was performed without complications, and the patient
survived for 21 months. Four patients (5.5%) who un-
derwent aortic or mitral VinV implantation and
received ASA and clopidogrel antiplatelet therapy
post-operatively developed valve thrombosis, which
was resolved with anticoagulation using warfarin.
One patient developed congestive heart failure
symptoms 1 year after transfemoral aortic VinV im-
plantation of a 23-mm SAPIEN valve into a 23-mm
Mitroﬂow surgical aortic tissue valve and subse-
quently underwent successful conventional redo
AVR. Pathology of the explanted SAPIEN valve
showed mild calciﬁcation. In this patient, residual
aortic stenosis was observed immediately following
VinV implantation (mean transaortic pressure gra-
dient 39 mm Hg and aortic valve area 0.8 cm2 at
1-month follow-up). One patient with aortic VinV
experienced cerebral hemorrhage due to a fall and
warfarin, which was resolved.
Signiﬁcant clinical improvement in heart failure
symptoms was observed following VinV implantation
in the majority of patients. In all patients who had
2-year follow-up data, NYHA functional class I and II
was observed in 82.8% and 100% patients with aortic
and mitral VinV implantation, respectively (Figure 2).
The majority of patients who had longer follow-up
after VinV implantation had NYHA functional class I
and II heart failure symptoms: 27 of 27 patients at the
third year, 14 of 15 patients at the fourth year, 6 of 6
patients at the ﬁfth year, and 4 of 4 patients at the
sixth year. One patient remained at NYHA functional
class I at 8 years.
PERFORMANCE OF TRANSCATHETER VALVES.
Transcatheter valve performance was determined by
echocardiography. A signiﬁcant reduction in prostheticvalvular pressure gradients and an increase in aortic
prosthetic valve areaswere seen at 12-month follow-up
in the survivors with aortic VinV implantation
(Figures 3E and 3G). A signiﬁcant reduction in mean
transmitral pressure gradient was also observed in
patients following transcatheter mitral VinV implan-
tation (Figure 3F). Aortic VinV implantation resulted
in signiﬁcant improvement in left ventricular ejection
fraction (LVEF) within 1-year follow-up in patients
who had baseline LVEF of #50% (Figure 3A). By
contrast, there was no improvement in LVEF in pa-
tients following mitral VinV implantation (Figure 3B).
PASP was signiﬁcantly decreased within 1 year
following aortic VinV implantation in the patients who
had baseline PASP of >50 mm Hg (p < 0.001)
(Figure 3C), but there was only a trend toward a
decrease in PASP in the patients who had mitral
VinV implantation (p ¼ 0.08) (Figure 3D). Further
analysis (F test on the basis of longitudinalmodelswith
covariance structure) showed that PASP and mean
TABLE 5 Inﬂuence of Surgical Valve Sizes on Transcatheter Valve Hemodynamics in
Aortic VinV Patients
Group
Surgical Valve
Size (mm)
THV Size
(mm)
Post-Op AVA
(cm2)
Post-Op MG
(mm Hg)
I (n ¼ 8) 19 or 21 20 or 23 0.88  0.15 25.7  9.5
II (n ¼ 14) 23 23 or 26 1.02  0.17* 22.5  7.9
III (n ¼ 19) 25, 27, or 29 23, 26, or 29 1.35  0.27*† 15.8  6.2*†
Values are mean  SD unless otherwise indicated. *p < 0.05 vs. Group I. †p < 0.05 vs. Group II.
AVA ¼ aortic valve area; MG ¼ mean gradient; Post-Op ¼ post-operative; THV ¼ transcatheter heart valve;
VinV ¼ valve in valve.
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1740gradient signiﬁcantly decreased with time following
either aortic or mitral VinV implantation (p < 0.001).
There was a continuing decrease in PASP from 12 to 36
months following mitral VinV implantation (Figure 4).
Of the patients who underwent aortic VinV im-
plantation, 4 (9.5%) had mild regurgitation and 38
(90.5%) had no or trivial regurgitation at up to 8-year
follow-up. In patients who underwent mitral VinV
implantation, 4 (12.9%) and 27 (87.1%) had mild and no
or trivial regurgitation at up to 5-year follow-up,
respectively. Following VinV implantation, no patient
had greater than mild regurgitation during follow-up.
DISCUSSION
Feasibility and good early outcomes associated with
transcatheter aortic and mitral VinV implantationFIGURE 2 Pre-Op and Post-Op NYHA Functional Class
Pre-operative (pre-op) and post-operative (post-op) New York Heart As
valve-in-valve (VinV) implantation in patients who had 24-month follow
class III and IV. M ¼ month follow-up.into failed surgical bioprostheses have been con-
ﬁrmed, but the mid-term and long-term outcomes
of transcatheter aortic and mitral VinV is unknown.
This study has demonstrated that transcatheter
VinV implantation provides encouraging mid-term
clinical and hemodynamic outcomes in this high-
risk elderly cohort of patients. The small surgical
valve size (19 and 21 mm) was an independent risk
factor for reduced survival in aortic VinV patients.
Long-term follow-up in a larger sample size is
needed to understand independent risk factors for
reduced survival, which will optimize patient
selection for the VinV procedure.
SURGICAL TECHNIQUES. In our center, transcatheter
aortic VinV implantation was initially performed us-
ing transapical access, which provided the most
direct, shortest, and coaxial access to the aortic valve.
However, more recently, the transfemoral approach
has gained favor, as it is similarly effective but rela-
tively less invasive. Transcatheter mitral valve im-
plantation has remained exclusively a transapical
procedure. Although the procedure can be replicated
with direct transseptal access, this remains a complex
procedure (18).
Initially, we routinely utilized valvuloplasty prior to
valve implantation. However, this has been found
largely unnecessary. Currently, we do not utilize
balloon valvuloplasty during transapical procedures,
although valvuloplasty still remains necessary insociation (NYHA) functional class following (A) aortic or (B) mitral
-up data. *p < 0.001 versus pre-op percentage of NYHA functional
FIGURE 3 Echocardiographic Outcomes Following Either Aortic or Mitral VinV Implantation In Patients Who Had
12-Month Follow-Up Data
(A and B) Left ventricular ejection fraction (LVEF) changes in patients with left ventricular dysfunction (pre-operative LVEF of #50%),
(C and D) changes in pulmonary artery systolic pressure (PASP) in patients with pulmonary hypertension (PASP >50 mm Hg), (E and F)
changes in mean transvalvular pressure gradient (MG), and (G) aortic valve area (AVA). Abbreviations as in Figure 2.
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1741some patientswith severe bioprosthetic aortic stenosis
undergoing a transarterial access procedure. Final
ﬁne adjustment of transcatheter valve positioning is
usually required during rapid ventricular pacing to
achieve an optimal positioning, as surgical valve mo-
tion particularly at the mitral position is signiﬁcant
during cardiac cycles. Therefore, slow inﬂation of a
balloon during valve deployment is strongly recom-
mended for VinV implantation.
EARLY CLINICAL OUTCOMES. A recent report from
the Global registry documented a 9.4% 30-day all-
cause mortality rate after aortic VinV implantation
in patients with an average Society of Thoracic Sur-
geons predicted risk of 11.8  9.9%. (19). Our 1.4%
30-day all-cause mortality compares very favorably,possibly due to our relatively large TAVI experience
prior to initiating VinV procedures. The size of sur-
gical mitral valves is generally much larger than that
of aortic surgical valves, which leads to better he-
modynamic outcomes following mitral VinV implan-
tation. Our 30-day mortality following mitral VinV
implantation was 0%.
Stroke following aortic TAVI is one of the major
concerns in patients with native aortic stenosis.
Degenerated bioprosthetic valve leaﬂets are generally
more friable than stenotic native valve leaﬂets and
prone to tearing, which theoretically leads to a higher
risk of acute neurological events. However, the inci-
dence of stroke in patients with VinV implantation is
equivalent to those in patients with TAVI for native
aortic stenosis. Our stroke rate was 1.4% following
FIGURE 4 Changes in Estimated Means of PASP and MG With Time Following
VinV Implantation
F test on the basis of longitudinal models with covariance structure showed that PASP and
MG signiﬁcantly decreased with time following either aortic or mitral VinV implantation
(p < 0.001). Abbreviations as in Figures 2 and 3.
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Heart block or aortic rupture was an extremely
rare complication because the transcatheter valve is
implanted into failed surgical valves without con-
tacting the aortic root or annulus.
Left main occlusion is a potentially fatal compli-
cation of TAVI, and may be even more common
in association with aortic VinV implantation. In this
VinV series, 1 patient experienced left main coronary
obstruction following aortic VinV implantation into
a failed Mitroﬂow aortic tissue valve. Following
this case, we initiated more extensive pre-operative
assessment for the risk of left main occlusion,
including routine screening with computed tomo-
graphic angiography. The size of sinus of Valsalva,
the height of a coronary ostium related to the height
of a surgical bioprosthetic leaﬂet, and the bulk of
a surgical bioprosthetic leaﬂet are the major de-
terminants of the risk for coronary ostial obstruction.
Generally speaking, stentless bioprosthetic valves or
those that are internally stented (e.g., Mitroﬂow and
Trifecta) may be at a slightly higher risk, as the leaf-
lets of these surgical valves may extend outward in
a tubular fashion following VinV implantation (17).
To avoid this signiﬁcant complication, careful pre-
operative assessment of the aortic root is still
important in patients undergoing the aortic VinV
procedure.MID-TERM CLINICAL OUTCOMES. Mid-term clinical
outcomes following VinV implantation were encour-
aging, with a 1-year survival of 88.9% and 5-year
survival of 40.5% in a very high-risk cohort. There
was no signiﬁcant difference in the survival following
aortic versus mitral VinV implantation. However,
later 5-year survival was relatively poor (40.5%),
likely a consequence of the multiple comorbidities
and advanced age of our patients, with the majority of
patients over age 80 years at the time of VinV im-
plantation. Peripheral vascular disease and history of
cerebrovascular accident are independent risk factors
for reduced survival following VinV implantation.
Female patients and patients with severe pulmonary
hypertension (pulmonary artery systolic pressure
of $60 mm Hg) appear to have poor survival
following VinV implantation. This study has also
demonstrated the signiﬁcant effect of failed surgical
valve size on clinical outcomes in patients undergo-
ing aortic VinV implantation. The patients with small
aortic surgical valve sizes (<23 mm) are associated
with signiﬁcantly poorer survival compared with
those with aortic valve sizes of $23 mm. Multivariate
analysis has demonstrated that the small size of the
aortic surgical valve is the only independent risk
factor of reduced survival.
Transcatheter VinV implantation provides signiﬁ-
cantly symptomatic relief and improved quality of
life in the majority of patients with either aortic or
mitral prosthetic disease. Symptomatic improvement
following VinV implantation is also seen in pa-
tients with small surgical bioprostheses sizes despite
relatively suboptimal hemodynamic performance
(small effective oriﬁce valve area and high residual
mean transaortic pressure gradient). The impro-
vement in symptoms and quality of life are persis-
tent in all survival patients during up to 8-year
follow-up.
TRANSCATHETER VALVE PERFORMANCE. The he-
modynamic performance of transcatheter valves
following VinV implantation is largely dependent on
the surgical valve size. The larger the surgical valve
size, the better the hemodynamics. The hemody-
namic performance of all mitral implants and in aortic
patients with surgical valve sizes of >23 mm is
excellent, with a low residual pressure gradient and a
relatively large effective oriﬁce. Residual stenosis of
an implanted transcatheter valve is rare in mitral
patients, as mitral surgical valves are generally $25
mm. In contrast, this is frequently seen in patients
with smaller aortic tissue valves (19 and 21 mm).
Left ventricular systolic function improves signiﬁ-
cantly following aortic VinV implantation, but not
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with the report following conventional aortic or
mitral valve replacement (20–22).
A signiﬁcant reduction in pulmonary artery pres-
sure following VinV implantation was observed in
both aortic and mitral patients. Unexpectedly, the
maximal reduction was immediately observed fol-
lowing aortic VinV implantation, whereas in patients
with mitral VinV implantation, a continuing decline
in pulmonary artery pressure was observed from 12 to
36 months. Although speculative, the pulmonary
hypertension is probably more chronic in patients
with mitral regurgitation than in patients with aortic
stenosis, which therefore requires more time for the
recovery following mitral VinV implantation. In
addition, this may be due to the higher incidence of
chronic lung disease in the mitral group.
Importantly, signiﬁcant paravalvular regurgitation
was not observed following VinV implantation into
either aortic or a mitral surgical bioprostheses.
The durability of aortic or mitral VinV implants is
encouraging at a median follow-up of 2.52 years with
maximum of 8 years follow-up. Structural failure
of transcatheter valves or valve reoperation was ob-
served only in 1 patient in our series. In this patient
who developed congestive heart failure and under-
went conventional redo AVR at 1 year following aortic
VinV implantation, the newly developed symptoms
are likely due to mismatch (small surgical valve),
rather than true structural valve dysfunction.
This is also supported by pathological study of the
explanted valve. Furthermore, the patient was only
53 years of age when she had the VinV implantation
and was also on hemodialysis; both are known to be
major risk factors for reduced longevity of surgical
bioprostheses.
CONSIDERATIONS OF SURGICAL VALVE SIZE.
VinV implants in smaller (19 and 21 mm) surgical
aortic valves were associated with signiﬁcant symp-
tomatic improvement. However, late survival was
disappointing. Whether this is the result of patient-
prosthesis mismatch and inadequate relief of aortic
stenosis or the consequence of the multiple factors
that lead to implantation of small surgical bio-
prostheses is unknown. It is also unknown if the
outcomes of redo surgical valve replacement in
conjunction with aortic root enlargement would be
better. However, it seems reasonable to recommend
caution when implanting intra-annular balloon-
expandable Sapien-type valves in small biopros-
theses. There is some evidence to suggest that better
hemodynamic outcomes may be achieved with
transcatheter valves that incorporate supra-annularleaﬂets (19,23,24), or smaller balloon-expandable
transcatheter valves (20 mm) (25).
In contrast, hemodynamic function was excellent
with encouraging clinical outcomes when VinV im-
plantation into larger (>23 mm) surgical bio-
prostheses. It seems reasonable to conclude that
surgeons should make every effort to implant surgical
aortic bioprostheses of at least 23 to 25 mm, particu-
larly in young patients. At the same time, it is sug-
gested to keep the valve away from the coronary ostia
to avoid coronary occlusion with VinV implantation.
If necessary to achieve these goals, enlargement of
the aortic annulus and/or aortic root (sinus Valsalva)
may be considered to allow future VinV therapy with
satisfactory outcomes. As an alternative, a more du-
rable mechanical valve might be considered.
POST-OPERATIVE ANTICOAGULATION. It has been
our practice to recommend aspirin indeﬁnitely and
clopidogrel for at least 3 months to patients following
native aortic valve TAVI. In aortic VinV patients, we
continue using the same protocol that is used in pa-
tients with TAVI. However, the observation of mitral
valve thrombus in 2 patients has led to our current
practice of aspirin indeﬁnitely with the addition of
warfarin for at least 3 months following mitral VinV
implantation in patients without atrial ﬁbrillation. An
embolic complication from either aortic or mitral valve
thrombosis appears rare, as we did not observe this in
our patients who were diagnosed with valve throm-
bosis. Clearly, optimal anticoagulation following VinV
therapy requires further study.
CONCLUSIONS
Transcatheter VinV implantation with balloon-
expandable valves for failed aortic or mitral surgical
bioprostheses can be performed safely with a high
success rate and minimal early mortality and
morbidity. Transcatheter VinV implantation provides
encouraging mid-term clinical and hemodynamic
outcomes in this high-risk elderly cohort of patients.
The appeal of this less-invasive approach to bio-
prosthetic valve failure may be compelling in patients
forwhom repeat surgerywould be high risk. In patients
undergoing conventional surgerywith a bioprosthesis,
efforts should be made to implant a bioprostheses
large enough to allow for a future VinV implant with
optimal hemodynamics and clinical outcomes.
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PERSPECTIVES
WHAT IS KNOWN? Feasibility and good early outcomes
associated with transcatheter aortic and mitral VinV im-
plantation into failed surgical bioprostheses have been
conﬁrmed, but the mid-term and long-term outcomes of
transcatheter aortic and mitral VinV is unknown.
WHAT IS NEW? Transcatheter VinV implantation pro-
vides encouraging mid-term clinical and hemodynamic
outcomes in this high-risk elderly cohort of patients. The
small surgical valve size (19 and 21 mm) was an inde-
pendent risk factor for reduced survival in aortic VinV
patients.
WHAT IS NEXT? Long-term follow-up in a larger sam-
ple size is needed to understand independent risk factors
for reduced survival, which will optimize patient selection
for the VinV procedure.
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